Antibody Discovery Services

OUR PROMISE
Delivering successful antibody leads for your development pipeline

On our mission to bridge the gap between research innovation and novel therapies, YUMAB has built an advanced discovery platform for next generation biotherapeutics. We provide access to challenging targets and new formats at high speed and success rate to lead drug developers worldwide through the discovery process as trusted, de-risking partner.

OUR PLATFORM
A powerful integraton of innovative technologies – rapid, robust, reliable

The YUMAB® platform provides all technologies for a fully integrated human antibody development in one company. We offer individually designed, work package-based contract research projects – from your target molecule to your engineered and optimized antibody lead candidate. Single technology modules or combinations thereof are also available as R&D service to assist your antibody program at every stage.

OUR DISCOVERY PROCESS
A 3-step fast track from target to lead

Hit Discovery

Generation of unique specific antibody hits for your target structure that bind in your designated assay.

Learn more

Lead Engineering

Optimization of selected antibody hits with the most promising binding characteristics with respect to affinity, specificity, selectivity or stability into early antibody lead candidates.

Learn more

Lead Development

Identification of the most developable early lead candidates and final polishing of the antibody sequences to your final lead candidate(s) for cell line development.

Learn more

Partner with us!

We support your race towards novel and better biotherapeutics with exceptional know-how, creativity, expertise and collaborative team spirit!

Get in touch

COVID-19 ANTIBODY DISCOVERY – A SUCCESS STORY

In the race for an effective treatment of hospitalized COVID-19 patients, YUMAB has launched an unparalleled fast track antibody development program in 2020 with only 11 months from bench to bedside: Within 4 months, the company had generated the patient-derived lead antibody COR-101 and only 4 months later the characterized functional antibody was forwarded to GMP production, followed by clinical development of COR-101 by YUMAB spin-out CORAT Therapeutics.

Download Case Study PDF